Table 1.
Adverse drug reactions reported through active and passive surveillance and dominant symptoms reported
| Rufiji District | Kilombero/Ulanga Districts1 | Total (%) | |
|---|---|---|---|
|
Total suspected adverse drug events reported |
45 |
50 |
95 (100) |
| Identified through active surveillance |
21 |
30 |
51 (53.7) |
| Identified through passive surveillance |
24 |
20 |
44 (46.3) |
| Number of cases successfully traced |
38 |
41 |
79 (83.2) |
|
Of the successfully traced cases: |
38 |
41 |
N = 79 (100) |
| Events associated with SP monotherapy |
20 |
33 |
53 (67.1) |
| Events associated with AS/SP combination therapy |
13 |
0 |
13 (16.5) |
| Events associated with AS monotherapy |
1 |
0 |
1 (1.3) |
| Events outside DSS area (excluded) |
3 |
5 |
8 (10.0) |
| Events unrelated to SP and/or AS (excluded) |
1 |
3 |
4 (5.0) |
|
Dominant symptoms reported for those included: |
34 |
33 |
N = 67 (100) |
| Body blisters and skin detachment |
7 |
11 |
18 (26.9) |
| Body swelling, itching and urticarial rashes |
10 |
6 |
16 (23.9) |
| Multiple lésions on mucus membranes |
6 |
7 |
13 (19.4) |
| Facial edema, sore mouth/nose conjunctiva |
5 |
4 |
9 (13.4) |
| Others1 |
6 |
5 |
11 (16.4) |
|
Deaths | |||
| Deaths attributable to SP and/or AS caused ADR | 2 | 4 | 6 (8.9%) |
1. These include side effects such as headache, lightheadedness, shortness of breath, stomachache, diarrhoea, vomiting and kidney pain.